Benoît Verjans has a PhD degree in biochemistry and a MBA from the University of Brussels. He has made a post-doctoral program at the University of Cambridge (UK). He worked at UCB Pharma in International Marketing, at McKinsey and Co as consultant mainly in pharma sector (marketing, supply chain and licensing projects) and as CEO of 4AZA Bioscience, a start-up from the University of Leuven developing new immuno-modulating drugs. He is currently Commercial Director of Aseptic Technologies, responsible of developing the sales of the closed vial technology worldwide. He is on the Editorial Board of Pharmaceutical Technology Europe and member of ISPE and PDA.